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Anaplastic thyroid cancer (ATC) is rare but extremely aggressive, which accounts for about 2% of all thyroid cancers yet nearly
50% of thyroid-cancer-associated deaths in the United States. The median survival time from diagnosis is 5 months, with a 1-year
survival rate of only 20%. We report here a case of ATC in a 56-year-old man who survived a large ATC. Preoperative ﬁne-needle
aspiration biopsy study to a large right thyroid mass suggested ATC. Total thyroidectomy with radical lateral neck and central neck
dissectionremovedawell-circumscribed9.5cmtumorwithoutextrathyroidalextensionorlymphovascularinvasion.All73lymph
nodes removed were negative for metastasis. The tumor consisted of highly pleomorphic, undiﬀerentiated cells with large zones of
necrosis and loss of thyroid transcription factor-1 and thyroglobulin expression. A focal well-diﬀerentiated component and PAX8
expression conﬁrmed its thyroid follicular cell origin. Nine months after postsurgical adjuvant concurrent radiation therapy and
chemotherapy, the patient remained well without clinical, biochemical, and radiographical evidence for cancer recurrence. This
is an unusual case of ATC in that it is one of the largest ATC tumors reported to display mild pathologic behavior and relatively
long-term patient survival.
1.CaseReport
The patient is a 56-year-old white man who presented
to his primary care physician one day after he noticed a
mass in his right neck. Computed tomography (CT) scan
conﬁrmed a large mass in his right neck arising from the
right thyroid lobe, measuring 5.4 × 5.2 × 9.1cm(Figure 1).
The CT also revealed a few lymph nodes without clear fatty
hila which measured 1-2cm in the right neck and upper
mediastinum. Two weeks later, the patient underwent a ﬁne-
needle aspiration biopsy of the thyroid mass, which revealed
highly malignant cells in a background of blood and necrotic
debris. The patient was then referred to our institution for
further management of suspected ATC.
The patient’s history was notable for a 55-pound weight
loss and fatigue, but he did not have compressive symptoms,
such as dysphagia or dyspnea, due to the mass. There was
no antecedent history of radiation exposure to the head and
neck. Physical exam revealed a large, visible mass extending
from the thyroid bed to the lateral aspect of the right neck,
occupying virtually the entire right anterior and lateral neck.
It extended also toward the left side beyond the midline. This
large mass was ﬁrm and nontender upon palpation and was
relatively immobile. The left thyroid lobe was unremarkable.
The trachea was diﬃcult to examine as it was covered by
the mass anteriorly. Neck ultrasonography revealed a large,
hypoechoic, irregular-shaped mass containing punctate cal-
ciﬁcations. A whole-body ﬂuorodeoxyglucose (18F) positron
emission tomography (PET) scan with high-resolution CT
demonstrated the right neck mass to be hypermetabolic and
revealed also a few hypermetabolic lymph nodes in the right
neck and upper mediastinum with no distant metastasis. A
Tc-99 MDP whole-body scan showed no metastatic disease
in the skeletal system. The esophageal muscularis, trachea,2 Case Reports in Medicine
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Figure 1: Preoperative computed tomography (CT) of the anaplastic thyroid carcinoma. (a) Axial view with contrast revealing a
heterogeneous mass that is intimately associated with the trachea and pushes it toward the left side of the neck but free of the common
carotid artery and the esophagus. (b) Coronal view with contrast demonstrating the craniocaudal extent and intimate tracheal involvement
of the tumor.
and carotid artery appeared to be well preserved structurally
on these imaging studies except for leftward deviation of the
trachea.Therewerenoabnormalimagingﬁndingstosuggest
distant metastasis.
Evaluation by the otolaryngology-head and neck surgery
consultation service at our institution, including a ﬁberoptic
laryngoscopy, was unremarkable except for the conﬁrmation
of a large right thyroid mass. Based on the clinical and diag-
nostic data, as well as conﬁrmation of the diagnosis of ATC
by our pathology department, our multidisciplinary thyroid
tumor team decided to pursue total thyroidectomy with
right and central neck dissections. Surgery was performed
three days after he transferred to our institution, which was
approximately one month from the time the patient ﬁrst
noted the neck mass. A well-circumscribed large thyroid
tumor was successfully removed, along with 73 lymph nodes
from the central and right lateral compartments of the neck
and the upper mediastinum.
Gross pathologic evaluation of the thyroid revealed one
9.5cm tumor with central necrosis and hemorrhage. The
tumor was partially encapsulated and completely conﬁned
within the thyroid gland. Histological evaluation revealed
an inﬁltrative malignant neoplasm with zones of geographic
tumor necrosis (Figure 2(a)). The tumor cells were undif-
ferentiated at the light microscopic level, with large and
highly pleomorphic nuclei containing prominent nucleoli
and numerous atypical mitoses, consistent with giant-cell
variant of ATC (Figure 2(b)). Although the neoplasm had
a predominantly giant cell pattern, there were also areas
of spindled (Figure 2(c)) and epidermoid (Figure 2(d))
histology. These were not osteoclast-like giant cells as seen
in a previously reported case of ATC with long survival of
the patient [1]. Focally admixed with the undiﬀerentiated
tumor was also a well-diﬀerentiated oncocytic component
(Figure 2(e)), which was localized centrally in the middle of
the tumor, accounting for about 10% of the entire tumor.
Anaplastic cells were throughout the rest of the tumor.
The well-diﬀerentiated component transitioned directly
into the predominant anaplastic component (Figure 2(f)).
The anaplastic carcinoma was positive for cytokeratins
AE1/AE3 (Figure 2(g))a n dP A X 8( Figure 2(h)). Only the
well-diﬀerentiated component but not the anaplastic com-
ponent of the tumor expressed thyroid transcription factor-
1( Figure 2(i)). The well-diﬀerentiated component but not
the anaplastic component also expressed thyroglobulin (data
not shown). These ﬁndings were consistent with anaplastic
thyroid carcinoma. Vascular invasion was not identiﬁed,
and the carcinoma did not extend beyond the thyroid. All
73 lymph nodes of the neck dissection were negative for
carcinoma.
Thyroxine replacement therapy was started postoper-
atively. Although there was no evidence to suggest local
or distant tumor invasion or metastasis, given the classical
aggressive nature of ATC in general, postoperatively the
patient received concurrent chemotherapy and external
beam radiation with weekly doxorubicin and docetaxel and
a total radiation of 6000cGy over a course of seven weeks.
During this treatment course, the patient suﬀered from
mild toxicity with discomfort in his upper chest, tightness
in the neck, some dysphagia, anemia, and leukopenia.
Nine months postoperatively, the patient remained well and
enjoyed his normal life without major issues except for
somemilddysphagia,necktightness,andchestchangesfrom
the radiation therapy. During the posttreatment course, the
patient had several surveillance imaging studies, including
neck ultrasonography, head/neck/chest CT, and whole-body
PET/CT scans, which were all negative for cancer recurrence
ormetastasis.Thehypermetaboliclymphnodesontheinitial
p r e o p e r a t i v eP E Ts c a nw e r en ol o n g e rs e e no nt h er e c e n t
postoperativesurveillancePETscan.Anechocardiogramwas
alsonormal.Hisserumthyroglobulinandcarcinoembryonic
antigen (CEA) were all undetectable during this course.Case Reports in Medicine 3
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Figure 2: Postoperative histopathology of the resected tumor. (a) The thyroid tumor featured large zones of necrosis (right) (hematoxylin
and eosin, ×100). (b) The tumor was composed of highly pleomorphic cells with large, bizarre nuclei containing prominent nucleoli and
mitoticﬁgures.Muchofthetumorwasinﬁltratedbyneutrophils,acommonfeatureofanaplasticthyroidcarcinoma(hematoxylinandeosin,
×400). While the predominant pattern of the tumor was pleomorphic/giant cell, there were areas that were spindled (c) hematoxylin and
eosin, ×200)orepidermoid(d)hematoxylinandeosin, ×200).(e)Focallyadmixedwiththeundiﬀerentiatedtumorwasawell-diﬀerentiated
oncocytic component (hematoxylin and eosin, ×200). (f) The well-diﬀerentiated component transitioned directly into the predominant
anaplastic component. The anaplastic carcinoma was positive for cytokeratins AE1/AE3 (g) (AE1/AE3 immunohistochemistry, ×200) and
PAX8 (h) (PAX8 immunohistochemistry, ×200). (i) The well-diﬀerentiated component of the tumor (right) expressed thyroid transcription
factor-1, while the anaplastic component (left) did not (thyroid transcription factor-1 immunohistochemistry, ×200).
2. Discussion
ATC is a rare but extremely aggressive and rapidly lethal
thyroid cancer derived from follicular epithelial thyroid cells;
in fact, it is one of the most deadly human cancers [2, 3].
Although this cancer accounts for only about 2% of all
thyroid malignancies, it is responsible for nearly half of
thyroid-cancer-related human deaths in the United States
[4]. An overall analysis of 1771 published cases of ATC
patients revealed median patient survival duration of only
ﬁve months and a median one-year survival rate of 20%
[3]. Extensive local invasion and lymph node metastasis of
the tumor with distant metastasis to lungs, bones, and other
partsofthebodyarecommonlyseenatthediagnosisofATC,
leaving the disease incurable and deadly at the early stage
after the diagnosis.
Our case of ATC was unusual in that although the tumor
represents one of the largest reported to date, there was no
local tumor invasion and even no extrathyroidal, venous,
and lymphatic invasion. Extensive neck dissection removed
a large number of lymph nodes, but none of them was
found to have metastasis. There was also no evidence of
distant metastasis either clinically or radiographically. Nine
months postoperatively, there was no clinical, biochemical,
and imaging evidence to suggest cancer recurrence and the
patient lives an essentially normal life, being able to return4 Case Reports in Medicine
to his work as a restaurant manager with normal function.
Despite the limited followup time interval of nine months,
the partially encapsulated nature and complete thyroidal
conﬁnement of this large tumor and absence of metastasis
at the time of diagnosis predict a more favorable long-term
outcome. As such, this case is outstanding and deviates
from the normal disease course in classical ATC patients.
There have been several case reports on patients with ATC
that showed an indolent clinical course with long-term
patient survival [5–13]. Most of these studies reported ATC
tumors of 2–5cm with recorded patient survival time of 2-
3 years, with the longest survival of more than 10 years in
a patient with a 5cm ATC [11]. The 9.5cm tumor of our
case thus represents one of the largest among the reported
ATC tumors while exhibiting no metastatic behavior. As
even small ATC tumors are usually lethally invasive and
aggressive, the lack of the classical aggressive features in
our case and those published similar cases suggest that a
subset of ATC tumors may behave diﬀerently than classical
ATC. Patients in this group of ATC seem to have an
excellent prognosis if complete surgical resection can be
accomplished. A striking pathological feature of our case
was its lack of extrathyroidal invasion and metastasis even
though the tumor size was extremely large, reﬂecting a
unique relatively indolent pattern of biological behavior of
ATC tumors in this group. This is likely the basis for the
good clinical outcome of our case as well as the similar
long-term survival cases published. Such cases attest to the
needformorefundamentalprognosticmarkersinevaluating
and treating ATC patients. ATC pathogenesis stems from
a complex array of genetic derangements, including gene
mutations and ampliﬁcations [2, 3, 14, 15]. We speculate
that the genetic alterations (or lack thereof) underlying
our case contribute to its unique outcome. It would be
interesting and important to identify such genetic alter-
ations that can help understand the biological basis of this
subset of ATC and guide their clinical prognostication and
management.
Given the lack of eﬀective medical treatment for ATC
currently, aggressive multimodal treatment customized on a
case-by-case basis, particularly after early diagnosis, remains
the treatment of choice for this cancer [2, 3, 16, 17]. When
this patient was seen by the medical endocrine team at
our institution, he was immediately referred and arranged
for surgical, medical oncology, and radiation oncology
consults. Because of the encouraging resectability of this
particular tumor shown on the preoperative CT study, our
multidisciplinary thyroid tumor review board opted for
surgery followed by adjuvant radiation and chemotherapy.
Although this case of ATC was not as invasive and aggressive
as is usually the case of ATC, the rapid multidisciplinary
management and forceful multimodal treatment of this
patient were appropriate given the currently limited under-
standing of ATC. We suggest that, as for classical aggressive
ATC, the same approach should remain the management
strategy for this unique subset of ATC until we can better
understand its biology and reliably predict its clinical
outcomes.
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